…researchers from the Penn’s department of Radiology and the Abramson Cancer Center used PET imaging and a novel radioactive tracer known as [18F]FluorThanatrace (FTT), to measure PARP-1 levels in 30 women with breast cancer with various subtypes before therapy, including surgery. They found that the PET imaging agent could effectively visualize and measure PARP-1 levels in all breast cancer tumors and metastases. {read more here}